Please login to the form below

Not currently logged in
Email:
Password:

amyloid plaque

This page shows the latest amyloid plaque news and features for those working in and with pharma, biotech and healthcare.

Germany’s Vivoryon raises €43m for Alzheimer’s drug trial

Germany’s Vivoryon raises €43m for Alzheimer’s drug trial

That decision “provides new evidence for the positive implications of amyloid plaque reduction in slowing cognitive decline” as well as a positive read-across for other approaches targeting amyloid beta, such ... Vivoryon isn’t the only company

Latest news

  • Biogen and Eisai drop Alzheimer’s drug elenbecestat Biogen and Eisai drop Alzheimer’s drug elenbecestat

    of Aβ peptides, which in turn would reduce amyloid plaque formations in the brain and slow the progression of Alzheimer’s. ... The antibody, which targeted soluble amyloid, had been due for its phase 3 read out in 2020.

  • Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms

    The hope has been that the drugs may reduce Aβ production, and thereby reduce amyloid plaque formations in the brain and in turn slow the progression of Alzheimer’s. ... Nevertheless David Reese says: "We still believe amyloid plays an important but

  • Takeda and Zinfandel abandon Alzheimer’s drug Takeda and Zinfandel abandon Alzheimer’s drug

    Meanwhile, other diabetes drugs have also been tested for activity in AD, including Novo Nordisk's Victoza (liraglutide) which seemed to reduce amyloid plaque formation but had no effect on cognitive

  • Biogen says trial extension data keep Alzheimer's drug on track Biogen says trial extension data keep Alzheimer's drug on track

    In both cases, the benefits on CDR-SB and MMSE extended into the second and third years and tracked significant decreases in amyloid plaque in the brains of patients. ... the negative trial had "minimal to no negative read across to the amyloid hypothesis

  • Novartis launches Alzheimer’s prevention study Novartis launches Alzheimer’s prevention study

    Like many other investigational Alzheimer's treatments solanezumab and gantenerumab are developed to work by targeting the build up of amyloid plaque in the brain. ... It is intended to trigger the body's immune system to fight the onset of amyloid.

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Interview: Jan Lundberg, Eli Lilly Interview: Jan Lundberg, Eli Lilly

    also an oral agent to implant the amyloid pathway that is planned to go into phase II this year. ... We also have an upcoming diagnostic opportunity in Alzheimer's: an imaging agent that can be used to detect amyloid plaque in the living human brain,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics